Hetero is one of the world’s leaders in HIV and AIDS medicine
Camber Pharmaceuticals’ parent company, Hetero, a global leader in active pharmaceutical ingredients (APIs) and generic drug manufacturing, is proud to announce a collaboration with the Gates Foundation to supply a generic version of lenacapavir for HIV prevention. This initiative will expand access to a powerful new prevention option for millions of people at risk of HIV in low- and middle-income countries: a low-cost, twice-yearly injectable pre-exposure prophylaxis (PrEP) therapy.
Gates Foundation Partners with Hetero
Through this new partnership—supported by upfront funding and volume guarantees—the Gates Foundation and Hetero will enable production of generic lenacapavir at approximately $40 per patient per year (following a short pre-treatment oral regimen). This affordable pricing model is designed to make the breakthrough preventive treatment sustainable and accessible for national health systems worldwide.
“Hetero is pleased to partner with the Gates Foundation to create a pathway for the sustainable and affordable supply of lenacapavir,” said Dr. Vamsi Krishna, Managing Director of Hetero Group of Companies. “This collaboration reflects our commitment to ensuring access to innovative HIV medicines for patients in India and other low- and middle-income countries.”
Two Decades of ARV Treatments
For over 20 years, Hetero has been one of the world’s leading providers of HIV and AIDS medicines, currently supplying approximately 40% of the global demand for antiretroviral therapies. Camber Pharmaceuticals is proud to support this mission by offering a growing portfolio of high-quality generic treatments for patients in the United States affected by HIV and AIDS.
To learn more about this initiative or other Camber products, please contact your Camber representative. You can read the full announcement on the Gates Foundation website: https://www.gatesfoundation.org/ideas/media-center/press-releases/2025/09/hiv-prevention-lenacapavir
